Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Day One Biopharmaceuticals (DAWN) Change in Receivables (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Receivables for 2 consecutive years, with $10.0 million as the latest value for Q4 2025.

For Q4 2025, Change in Receivables rose 93.75% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $12.9 million, down 7.33%, while the annual FY2025 figure was $12.9 million, 7.33% down from the prior year.
Change in Receivables was $10.0 million for Q4 2025 at Day One Biopharmaceuticals, up from -$3.0 million in the prior quarter.
The five-year high for Change in Receivables was $10.0 million in Q4 2025, with the low at -$3.0 million in Q3 2025.